| Martin Olin, EMBA, M.Sc. |
Chief Executive Officer
Before joining Symphogen, Mr. Olin served as Senior Investment Manager at Scandinavian Life Science Invest (SLS Invest). Prior to his position with SLS Invest, Olin was the Finance Director, EMEA for Novo Nordisk managing finance, IT and customer service for the region. Mr. Olin has more than a decade of executive experience with life science companies and has been involved in numerous private equity transactions, trade sales and commercial partnerships. Mr. Olin serves as director on the board of several life science companies in the US and in Europe.
| Ivan D. Horak, MD, FACP |
Head of Global R&D, Chief Scientific and Medical Officer
Prior to joining Symphogen, Dr. Horak served as President of Research and Development and Chief Scientific Officer of Enzon Pharmaceuticals Inc. Before that, Dr. Horak served as Chief Scientific Officer of Immunomedics, responsible for development of novel antibodies. Dr. Horak has authored over 70 peer-reviewed publications and several book chapters within the fields of hematology, oncology, and immunology and has served on the editorial boards of several scientific journals. Dr. Horak is board certified oncologist. He is Fellow of American College of Physicians and member of American Association for Cancer Research, American Society of Hematology, and American Society Clinical Oncology.
| Mads Laustsen, M.Sc. |
Chief Manufacturing Officer
| Jesper Bramming, M.Sc. Economics |
Chief Financial Officer